Treatment-resistant hypertension
Conditions
Brief summary
Change in systolic blood pressure (sBP) from baseline on combined citrulline, folic acid, vericiguat and tadalafil treatment versus combined citrulline, folic acid and vericiguat as measured by 24-hour ABPM.
Detailed description
Changes in office sBP from baseline, incidence of achieving target office sBP (<140 mmHg), diastolic blood pressure (dBP) from baseline, in office dBP from baseline, number of circulatory mature endothelial cells (CEC), as well as change in albumin/creatinine ratio in morning spot urine will be explored.
Interventions
DRUGTadalafil Krka 5 mg filmdragerade tabletter
DRUGFolsyra Evolan 5 mg tablett
Sponsors
Karolinska University Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in systolic blood pressure (sBP) from baseline on combined citrulline, folic acid, vericiguat and tadalafil treatment versus combined citrulline, folic acid and vericiguat as measured by 24-hour ABPM. | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in office sBP from baseline, incidence of achieving target office sBP (<140 mmHg), diastolic blood pressure (dBP) from baseline, in office dBP from baseline, number of circulatory mature endothelial cells (CEC), as well as change in albumin/creatinine ratio in morning spot urine will be explored. | — |
Countries
Sweden
Outcome results
None listed